AUTHORS
Meesha Vullikanti, MS, Valentina Restrepo, M.D.2, Bria Carrithers, M.D., M.S.3, Alexandra Galls, MD4, Ryan Hunt, M.D.5, Maureen Okam Achebe Jr, MD, MPH6, Sharl Azar, MD7, Nancy Berliner Jr, MD8, Jean M. Connors, MD9, Elizabeth Klings, MD10, Arielle Lyon Langer, MD MPH11, Thomas F McElrath, MD, PhD12, Patrick T. McGann, MD13, Deborah Michelle Siegal, MD MSc FRCPC14, Lauren E Merz, MD, MSc15, Layla N. Van Doren, MD, MBA16
AFFILIATIONS
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Medicine, New Haven, Connecticut, United States
3 Yale School of Medicine, New Haven, Connecticut, United States
4 Brigham & Women's Hospital, Boston, Massachusetts, United States
5 University of Michigan, Ann Arbor, Michigan, United States
6 Brigham & Women's Hospital, Boston, Massachusetts, United States
7 Massachusetts General Hospital, Boston, Massachusetts, United States
8 Brigham & Women's Hospital, Boston, Massachusetts, United States
9 Brigham & Women's Hospital, Boston, Massachusetts, United States, Dana Farber Cancer Institute, Boston, Massachusetts, United States
10 Boston University School of Medicine, Boston, Massachusetts, United States
11 Brigham & Women's Hospital, Boston, Massachusetts, United States
12 Brigham & Women's Hospital, Boston, Massachusetts, United States
13 Brown University, Providence, Rhode Island, United States
14 University of Ottawa, Ottawa, Ontario, Canada
15 University of Michigan, Ann Arbor, Michigan, United States
16 University of California San Francisco, San Francisco, California, United States
ABSTRACT
Background: Sickle cell disease (SCD) is associated with a high burden of adverse outcomes in pregnancy and the postpartum period, including a significant increase in the risk of pregnancy loss. Much of the work exploring pregnancy loss in SCD is complicated by underreporting and misclassification of pregnancy outcomes including subfertility, spontaneous pregnancy loss, and recurrent pregnancy loss in ICD-10 code-based research. This study aimed to describe the association between prior pregnancy loss, therapy impacting disease burden such as transfusions and disease-modifying therapy, and obstetric and SCD outcomes in a multi-center pregnant and postpartum SCD patient cohort.
Methods: We conducted a multi-center retrospective-prospective cohort study of SCD pregnancies from 2015 to 2025 across 3 tertiary care academic centers. SCD diagnosis was confirmed via hemoglobin electrophoresis. Demographic and clinical characteristics, including obstetric history, SCD co-morbidities, disease-modifying therapy, and laboratory data were collected from 1 year prior to conception through 90 days postpartum. For analysis, participants and pregnancies were stratified according to pregnancy loss history: nulliparous (G1P0), multiparous without a history of loss (G>1P1), and multiparous with a history of loss (G>1P0). Pregnancy loss was defined as any elective or spontaneous loss of pregnancy at any gestational age. Primary endpoint was incidence of adverse pregnancy outcomes, such as postpartum hemorrhage and preterm delivery. Secondary outcomes included postpartum SCD-related complications and differences in therapy decreasing disease burden (such as transfusions or hydroxyurea) across the study period. Significance testing was completed using Chi-square tests of independence and Fisher’s exact test for categorical variables and Kruskal-Wallace rank sum testing for continuous variables.
Results: 162 pregnancies from 114 participants were included in this analysis. 29 (25%) participants were G1P0, 23 (20%) were G>1P1, and 62 (54%) were G>1P0. Median (IQR) age was 26 (6.5) for the G1P0 group, 29 (4) for the G>1P1 group, and 31 (8) for the G>1P0 group. There was a significant difference in hemoglobin genotype when stratified by prior pregnancy loss: a greater proportion with a history of pregnancy loss had HbSC disease (28%), HbS-beta+ (13%), or HbS-beta0 (7%); p=0.015) compared with those with HbSS disease.
Obstetric and SCD clinical features were evaluated at a per-pregnancy level. There were 31 (19%) G1P0 pregnancies, 36 (22%) G>1P1 pregnancies, and 95 (58%) G>1P0 pregnancies. Median (IQR) number of pregnancy losses was 1 (1). Of the 95 pregnancies of G>1P0 patients, 81 (86%) had at least 1 spontaneous abortion and 24 (25%) had at least 1 prior elective abortion. 16 (17%) of pregnancies were notable for a history of second trimester spontaneous loss or fetal loss and 30 (31%) were notable for a history of recurrent pregnancy loss (>1 spontaneous abortion or fetal loss). G>1P0 pregnancies were also found to less often be on pre-pregnancy hydroxyurea (22% as compared to 38% for nulliparous pregnancies; p=0.025). During pregnancy, G>1P0 pregnancies were less likely to be associated with planned transfusion (8% as compared to 25% for G1P0 pregnancies and 20% in G>1P1 pregnancies; p=0.007).
147 of the 162 pregnancies followed in the study ended in live births. G>1P0 pregnancies were associated with higher rates of urgent or emergent cesarean delivery (34% as compared to 30% in G1P0 pregnancies and 11% in G>1P1 pregnancies; p=0.004). G>1P0 pregnancies were also associated with higher rates of postpartum re-admission for obstetric complications (15% as compared to 0% for G1P0 pregnancies and 13% for G>1P1 pregnancies; p=0.02)
Conclusions: For those with SCD, pregnancies among those with prior pregnancy loss were associated with a higher incidence of urgent or emergent cesarean delivery and readmission for obstetric complications. Prior to pregnancy and during the prenatal period, patients with prior fetal loss had lower usage of disease modifying therapies, including pre-pregnancy hydroxyurea use and planned transfusions during pregnancy. These results raise questions of the importance of aggressive disease management prior to conception and during pregnancy for patients with SCD with prior pregnancy loss. Future work should explore care utilization characteristics and disease severity during pregnancy for SCD patients with pregnancy loss.
DISCLOSURES
Meesha Vullikanti, MS: No relevant conflicts of interest to declare.